Retartrutide 10mg

Retatrutide is an investigational “triple agonist” peptide that simultaneously targets GLP-1, GIP, and glucagon receptors, offering a comprehensive approach to metabolic regulation. By combining these mechanisms, retatrutide enhances energy expenditure, improves insulin sensitivity, and promotes significant appetite suppression. The inclusion of glucagon receptor activity distinguishes it from dual agonists, contributing to increased caloric expenditure and fat oxidation.

Early-phase clinical trials have shown that retatrutide can induce substantial and sustained weight loss, with some participants achieving reductions exceeding 20% of baseline body weight. Improvements in glycemic control, liver fat content, and cardiometabolic risk markers have also been reported. While these results are highly promising, retatrutide remains under investigation, and further large-scale studies are required to establish its safety profile, optimal dosing strategies, and long-term clinical outcomes.